CL2022003390A1 - Métodos para tratar o prevenir las infecciones de sars-cov-2 y covid-19 con anticuerpos antiglicoproteína de espiga de sars-cov-2. - Google Patents

Métodos para tratar o prevenir las infecciones de sars-cov-2 y covid-19 con anticuerpos antiglicoproteína de espiga de sars-cov-2.

Info

Publication number
CL2022003390A1
CL2022003390A1 CL2022003390A CL2022003390A CL2022003390A1 CL 2022003390 A1 CL2022003390 A1 CL 2022003390A1 CL 2022003390 A CL2022003390 A CL 2022003390A CL 2022003390 A CL2022003390 A CL 2022003390A CL 2022003390 A1 CL2022003390 A1 CL 2022003390A1
Authority
CL
Chile
Prior art keywords
cov
sars
methods
covid
infections
Prior art date
Application number
CL2022003390A
Other languages
English (en)
Inventor
Sumathi Sivapalasingam
Samit Ganguly
Jennifer Hamilton
Gary Herman
Andrea Hooper
Flonza Isa
Meagan O'brien
Kenneth Turner
Neto Eduardo Forleo
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of CL2022003390A1 publication Critical patent/CL2022003390A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1002—Coronaviridae
    • C07K16/1003—Severe acute respiratory syndrome coronavirus 2 [SARS‐CoV‐2 or Covid-19]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin

Abstract

La presente invención proporciona métodos para prevenir y tratar infecciones por SARS-CoV2, COVID-19, o síntomas de estos. Los métodos de la invención presentan la administración de una o más moléculas de unión al antígeno (p. ej., anticuerpos) que se unen a una proteína de superficie de SARS-CoV-2 (p. ej., proteína espicular).
CL2022003390A 2020-06-03 2022-11-30 Métodos para tratar o prevenir las infecciones de sars-cov-2 y covid-19 con anticuerpos antiglicoproteína de espiga de sars-cov-2. CL2022003390A1 (es)

Applications Claiming Priority (33)

Application Number Priority Date Filing Date Title
US202063034348P 2020-06-03 2020-06-03
US202063036956P 2020-06-09 2020-06-09
US202063038274P 2020-06-12 2020-06-12
US202063043336P 2020-06-24 2020-06-24
US202063060592P 2020-08-03 2020-08-03
US202063062961P 2020-08-07 2020-08-07
US202063065799P 2020-08-14 2020-08-14
US202063085066P 2020-09-29 2020-09-29
US202063084881P 2020-09-29 2020-09-29
US202063089399P 2020-10-08 2020-10-08
US202063090690P 2020-10-12 2020-10-12
US202063094133P 2020-10-20 2020-10-20
US202063105779P 2020-10-26 2020-10-26
US202063106696P 2020-10-28 2020-10-28
US202063112140P 2020-11-10 2020-11-10
US202063116773P 2020-11-20 2020-11-20
US202063119593P 2020-11-30 2020-11-30
US202063120065P 2020-12-01 2020-12-01
US202063124980P 2020-12-14 2020-12-14
US202063131627P 2020-12-29 2020-12-29
US202163141423P 2021-01-25 2021-01-25
US202163141952P 2021-01-26 2021-01-26
US202163142471P 2021-01-27 2021-01-27
US202163144789P 2021-02-02 2021-02-02
US202163150978P 2021-02-18 2021-02-18
US202163162504P 2021-03-17 2021-03-17
US202163162996P 2021-03-18 2021-03-18
US202163164488P 2021-03-22 2021-03-22
US202163165654P 2021-03-24 2021-03-24
US202163166187P 2021-03-25 2021-03-25
US202163173468P 2021-04-11 2021-04-11
US202163185301P 2021-05-06 2021-05-06
US202163186029P 2021-05-07 2021-05-07

Publications (1)

Publication Number Publication Date
CL2022003390A1 true CL2022003390A1 (es) 2023-05-26

Family

ID=78829987

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2022003390A CL2022003390A1 (es) 2020-06-03 2022-11-30 Métodos para tratar o prevenir las infecciones de sars-cov-2 y covid-19 con anticuerpos antiglicoproteína de espiga de sars-cov-2.

Country Status (14)

Country Link
US (1) US20210395345A1 (es)
EP (1) EP4161960A1 (es)
JP (1) JP2023528441A (es)
KR (1) KR20230019166A (es)
CN (1) CN116057069A (es)
AU (1) AU2021283349A1 (es)
BR (1) BR112022024662A2 (es)
CA (1) CA3181026A1 (es)
CL (1) CL2022003390A1 (es)
CR (1) CR20220660A (es)
IL (1) IL298425A (es)
MX (1) MX2022014852A (es)
TW (1) TW202210506A (es)
WO (1) WO2021247779A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10787501B1 (en) 2020-04-02 2020-09-29 Regeneron Pharmaceuticals, Inc. Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments
WO2023122211A2 (en) * 2021-12-21 2023-06-29 Duke University Coronavirus antibodies and uses thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1914244E (pt) 1999-04-09 2013-07-26 Kyowa Hakko Kirin Co Ltd Processo para regular a actividade de moléculas funcionais sob o ponto de vista imunológico
US7737725B1 (en) 2008-04-04 2010-06-15 Xilinx, Inc. Device control register for a processor block
KR101441437B1 (ko) 2009-06-02 2014-09-25 리제너론 파마슈티칼스 인코포레이티드 푸코실화-결핍 세포
TWI635098B (zh) 2013-02-01 2018-09-11 再生元醫藥公司 含嵌合恆定區之抗體
JP6773679B2 (ja) 2015-03-30 2020-10-21 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． Ｆｃガンマ受容体に対する結合が低下した重鎖定常領域
CN111088283B (zh) * 2020-03-20 2020-06-23 苏州奥特铭医药科技有限公司 mVSV病毒载体及其病毒载体疫苗、一种基于mVSV介导的新冠肺炎疫苗
US10787501B1 (en) * 2020-04-02 2020-09-29 Regeneron Pharmaceuticals, Inc. Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments
US20210388065A1 (en) * 2020-04-15 2021-12-16 Active Motif Shanghai Limited Antibodies to sars-coronavirus (covid-19) s1 spike protein

Also Published As

Publication number Publication date
TW202210506A (zh) 2022-03-16
CN116057069A (zh) 2023-05-02
CR20220660A (es) 2023-02-17
MX2022014852A (es) 2023-02-01
AU2021283349A1 (en) 2023-02-02
JP2023528441A (ja) 2023-07-04
BR112022024662A2 (pt) 2023-04-04
US20210395345A1 (en) 2021-12-23
WO2021247779A1 (en) 2021-12-09
KR20230019166A (ko) 2023-02-07
CA3181026A1 (en) 2021-12-09
IL298425A (en) 2023-01-01
EP4161960A1 (en) 2023-04-12

Similar Documents

Publication Publication Date Title
CL2023000705A1 (es) Anticuerpos contra glicoproteína de espícula anti-sars-cov-2 y fragmentos de unión al antígeno
CL2022003390A1 (es) Métodos para tratar o prevenir las infecciones de sars-cov-2 y covid-19 con anticuerpos antiglicoproteína de espiga de sars-cov-2.
CL2020003422A1 (es) Anticuerpos que se dirigen al gp120 de vih y métodos de uso
ECSP21023859A (es) Composiciones y métodos para el tratamiento de infecciones virales
BR112016030686A2 (pt) anticorpos anti tau humanizados
BR112017014308A2 (pt) anticorpos biespecíficos contra calicreína plasmática e fator xii
CO2020013833A2 (es) Anticuerpo anti-muerte programada-ligando 1 y su uso
BR112022000503A2 (pt) Compostos úteis para tratar infecções por vírus influenza
UY39135A (es) ANTICUERPOS MONOCLONALES HUMANOS DIRIGIDOS CONTRAEL CORONAVIRUS 2 DEL SÍNDROME RESPIRATORIO AGUDO GRAVE (SARS-CoV-2)
PE20230160A1 (es) Anticuerpos especificos para cd47, pd-l1 y sus usos
BR112022024149A2 (pt) Anticorpos antiglicoproteína spike de anti-sars-cov-2 e fragmentos de ligação a antígeno
PE20181176A1 (es) Composiciones biofarmaceuticas
CO2021008665A2 (es) Tratamiento de cefalea por uso excesivo de medicamentos usando anticuerpos anti-cgrp o anti-cgrp-r
ECSP22026797A (es) Composiciones y métodos para el tratamiento de infecciones virales
CL2021003215A1 (es) Anticuerpos anti-pcrv que se unen a pcrv, composiciones que comprenden anticuerpos anti-pcrv, y métodos de uso de estos
CO2022009696A2 (es) Anticuerpo anti-lilrb1 y usos del mismo
CO2021014153A2 (es) Anticuerpo monoclonal que se une específicamente a gitr
DOP2023000074A (es) Compuestos fosfolípidos y usos de estos
AR115257A1 (es) Anticuerpos de fijación a bcma y sus usos
CO2023000070A2 (es) Moléculas de anticuerpo contra el virus bk
CO2019012204A2 (es) Proteínas de unión al antígeno anti-jagged1
CL2023000121A1 (es) Anticuerpos anti-il-36r para el tratamiento de dermatosis neutrófilas
DOP2023000039A (es) Moléculas de unión a antígeno multi-específicas contra el vih y métodos de uso
CO2023000557A2 (es) Anticuerpos y métodos para tratar enfermedades asociadas a claudina
CL2022001545A1 (es) Composiciones y métodos para tratar y prevenir la influenza